Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide–bortezomib combinations

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2141|169|6|843-850

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.169, Iss.6, 2015-06, pp. : 843-850

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Extramedullary disease in multiple myeloma in the era of novel agents

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 6, 2015-06 ,pp. : 763-765

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment of Multiple Myeloma: Thalidomide-, Bortezomib-, and Lenalidomide-Induced Peripheral Neuropathy

By  

Oncology Research and Treatment, Vol. 37, Iss. 9, 2014-08 ,pp. : 506-513

Karger

Access to resources Recommend Favorite

A new staging system to predict prognosis of patients with multiple myeloma in an era of novel therapeutic agents

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 94, Iss. 2, 2015-02 ,pp. : 145-151

John Wiley & Sons Inc

Access to resources Recommend Favorite

Survival of Multiple Myeloma Patients Aged 65-70 Years in the Era of Novel Agents and Autologous Stem Cell Transplantation

By  

Acta Haematologica, Vol. 132, Iss. 2, 2014-03 ,pp. : 211-219

Karger

Access to resources Recommend Favorite

Real‐world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents

By  

JOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Vol. 269-4727, Iss. 1, 2013-02 ,pp. : 41-47

John Wiley & Sons Inc

Access to resources Recommend Favorite